MRD-guided Tislelizumab After Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer (NSCLC)
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This is a single-center, single-arm phaseâ…¡trial to explore a follow-up intervention mode
after curative treatment for resected stage II/III NSCLC. MRD monitoring for recurrence in
order to give earlier intervention to reduce the recurrence rate and improve the survival
rate, and to evaluate the efficacy and safety of tislelizumab after adjuvant chemotherapy in
resected NSCLC